Cme Group INC Form 4 insider transactions

CME Group Director Elizabeth A. Cook acquired 532 shares of Common Stock Class A at $273.03 per share on June 25, 2025, increasing her beneficial ownership.

CME Group Inc. Director Timothy S. Bitsberger acquired 532 shares of Common Stock Class A at a price of $273.03 per share, increasing his total beneficial ownership to 11,121 shares, as part of the company's Director Stock Plan.

CME Group Inc. Director Rahael Seifu has reported the future acquisition of 532 shares of Common Stock Class A, valued at $273.03 per share, effective June 25, 2025, as part of the company's Director Stock Plan.

CME Group Inc. Director Patrick J. Mulchrone has filed a Form 4 indicating a future acquisition of 532 shares of Class A Common Stock on June 25, 2025, as part of the company's Director Stock Plan.

Phyllis M. Lockett, a Director at CME Group Inc., increased her stake in the company by acquiring 532 shares of common stock at a price of $273.03 per share.

CME Group Inc. Director Deborah J. Lucas acquired 532 shares of Common Stock Class A at a price of $273.03 per share on June 25, 2025, increasing her total beneficial ownership to 3,888 shares.

CME Group Inc. Director Bryan T. Durkin acquired 532 shares of Common Stock Class A at a price of $273.03 per share, increasing his beneficial ownership to 47,207 shares, as part of the company's Director Stock Plan.

CME Group Inc. Director Daniel G. Kaye acquired 532 shares of Common Stock Class A on June 25, 2025, as part of the company's Director Stock Plan, increasing his total beneficial ownership to 4,200 shares.

CME Group Inc. Director Charles P. Carey was granted 879 shares of Class A Common Stock as part of the company's Director Stock Plan, increasing his beneficial ownership.

CME Group Inc. Director William W. Hobert reported the acquisition of 879 shares of Class A Common Stock at a price of $273.03 per share, granted under the company's Director Stock Plan.

CME Group Inc. Director Martin J. Gepsman acquired 532 shares of Common Stock Class A at $273.03 per share, increasing his beneficial ownership to 25,299 shares, as reported in a recent SEC Form 4 filing.

CME Group Inc. Director Howard J. Siegel acquired 879 shares of Common Stock Class A on June 25, 2025, through the company's Director Stock Plan.

CME Group Inc. Director Dennis Suskind acquired 532 shares of Common Stock Class A at $273.03 per share on June 25, 2025, as part of the company's Director Stock Plan.

CME Group Inc. Director Kathryn Benesh acquired 532 shares of common stock at $273.03 per share on June 25, 2025, as part of the company's Director Stock Plan.

CME Group Inc. Director Robert J. Tierney Jr. acquired 532 shares of common stock at $273.03 per share, increasing his direct beneficial ownership to 13,700 shares, as part of the company's Director Stock Plan.

CME Group Director William R. Shepard has reported the acquisition of additional Class A common stock through a stock plan grant and dividend reinvestment, increasing his beneficial ownership.

CME Group Inc. Director Charles P. Carey reported the sale of 500 shares of Class A Common Stock for approximately $132,676.50 on June 10, 2025, as part of a Rule 10b5-1 plan.

CME Group Director Daniel G. Kaye reported the sale of 500 shares of Common Stock Class A at a price of $282.4193 per share on May 22, 2025, reducing his direct beneficial ownership to 3,668 shares, as part of a pre-scheduled Rule 10b5-1 plan.

Jonathan L. Marcus, Sr MD General Counsel of CME Group Inc., sold 390 shares of Common Stock Class A at $277.5 per share on May 20, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Phyllis M. Lockett, a director of CME Group Inc., sold 1,060 shares of Class A common stock on May 19, 2025, at a weighted average price of $277.88 per share.

Director Martin J. Gepsman sold 300 shares of CME Group Inc. common stock at a price of $273.17 on May 15, 2025.

Charles P. Carey, a director of CME Group Inc., sold 3,000 shares of Class A common stock on May 15, 2025, at a weighted average price of $272.56.

Derek Sammann, a Senior Managing Director at CME Group, reported the acquisition and disposal of CME Group Class A common stock through direct and indirect ownership.

Derek Sammann, Senior Managing Director at CME Group, amends his Form 4 to reflect changes in beneficial ownership following a performance share award and a transfer of stock to a revocable living trust.

Director Dennis Suskind sold 1,000 shares of CME Group Class A common stock at an average price of $271.28 on April 29, 2025.

Director Larry Gerdes sold a total of 4,000 shares of CME Group Class A common stock in late April 2025.

William Shepard, a director at CME Group, increased his holdings of Class A Common Stock through a dividend reinvestment plan.

William Shepard, a director at CME Group, amended his Form 4 filing to reflect an updated number of shares acquired through a dividend reinvestment plan.

Director Deborah J. Lucas sold 1,500 shares of CME Group Inc. stock at a price of $256.95 on March 14, 2025.

CME Group's Chief Transformation Officer, Ken Vroman, reports acquisition of shares from a performance share award and subsequent surrender of shares to cover tax obligations.